Abbisko (和誉) IPO: Fairly Valued for the Early Stage of Clinical Trials
We provide an update for Abbisko's book building. We run the deal through our ECM framework and provide our thoughts on the deal.
398 Views
Abbisko (和誉) Pre-IPO: Thoughts on Valuation
We provide forecast and valuation for the Abbisko's two core products, ABSK011 and ABSK091, as well as the SOTP valuation for the company's asset.
409 Views
Abbisko IPO: Some Products Show Good Potential but Too Early to Assess Their Success
Abbisko’s development pipeline is comprised of drugs that could become breakthrough therapies in the future, however, these product candidates are...
350 Views
ECM Weekly (26th September 2021) - Hanyu Med, Abbisko, SenseTime, ANE, Nykaa, Prudential HK
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
566 Views
Abbisko IPO: A Promising but Longer Term Prognosis
While both core products are at an early stage of development, promising trials, management’s track record and blue-chip backers suggest that the...
486 Views